Mustang Bio, Inc. announced that interim Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL), have been selected for a poster presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy (ASTCT) and Center for International Blood & Marrow Transplant Research (CIBMTR), taking place February 2 6, 2022 in Salt Lake City, Utah (2022 Tandem Meetings). MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Research Center (Fred Hutch).
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4865 USD | -12.97% |
|
+9.62% | -63.96% |
21/06 | Sector Update: Health Care Stocks Steady Premarket Friday | MT |
20/06 | Mustang Bio to Raise $2.5 Million From Share Offering | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-63.96% | 15.18M | |
+15.58% | 121B | |
+16.60% | 110B | |
+17.73% | 25.93B | |
-24.33% | 19.27B | |
-19.35% | 16.01B | |
-17.95% | 15.66B | |
-48.32% | 14.89B | |
+58.78% | 14.47B | |
+4.91% | 13.91B |
- Stock Market
- Equities
- MBIO Stock
- News Mustang Bio, Inc.
- Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR